Kidney bean

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Spookley the Square Pumpkin Celebrates Easter With New Shorts on Disney Junior and DisneyNOW

Retrieved on: 
Wednesday, April 6, 2022 - 3:00pm

WILTON, Conn., April 6, 2022 /PRNewswire-PRWeb/ -- LINK TO PHOTOS

Key Points: 
  • begins airing in rotation April 8 on Disney Junior and will be available that same day on Disney Junior YouTube and in DisneyNOW.
  • The Spookley Easter Show will debut April 8 in DisneyNOW and on the Official Spookley YouTube channel.
  • For more information about Spookley the Square Pumpkin and Holiday Hill Farm, please visit the official Spookley website ( spookley.com ) and follow Spookley on Facebook ( facebook.com/Spookley/ ) and Instagram ( @spookleythesquarepumpkin ).
  • Holiday Hill Enterprises is the production company behind literary-based franchise Spookley the Square Pumpkin and Holiday Hill Farm.

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022 - 12:00am

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

Organic Superfood Pioneer Navitas Organics Roots Itself in Superfoods with Purpose™ - A Commitment to Creating a Healthier World through Regenerative Organic Farming and Plant-Based Lifestyles

Retrieved on: 
Friday, March 4, 2022 - 9:08pm

NOVATO, Calif., March 4, 2022 /PRNewswire/ -- Navitas Organics , the organic superfood pioneer, has announced the rollout of Superfoods with Purpose ,a credo that underscores the company's ongoingcommitment to creating a healthier world through regenerative organic farming and plant-based lifestyles.

Key Points: 
  • NOVATO, Calif., March 4, 2022 /PRNewswire/ -- Navitas Organics , the organic superfood pioneer, has announced the rollout of Superfoods with Purpose ,a credo that underscores the company's ongoingcommitment to creating a healthier world through regenerative organic farming and plant-based lifestyles.
  • Superfoods with Purpose encompasses who we are and our commitment to uphold our mission."
  • We are committed to creating a healthier world through regenerative organic farming and plant-forward lifestyles.
  • We hope you join us in our Superfoods with Purpose commitment by connecting with us on navitasorganics.com , and on Instagram , Facebook , and Twitter .

Experimental Compound Counters Diabetic Complications

Retrieved on: 
Wednesday, November 24, 2021 - 7:00pm

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.

Key Points: 
  • NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.
  • The results revolve around the body's immune system, which recognizes and destroys invading bacteria and viruses.
  • Experiments in human cells and mouse models found that the lead study compound, RAGE229, significantly reduced short- and long-term complications of diabetes.
  • The team next incorporated the RAGE229 molecule into mouse chow because dietary intake could better measure its ability to reverse long-term complications like diabetic wounds.

DGAP-News: MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

Retrieved on: 
Wednesday, October 20, 2021 - 9:31pm

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
  • "Dosing of the first IgAN patient is an exciting milestone for MorphoSys, physicians and patients alike as we are rapidly broadening our development program for felzartamab."
  • Felzartamab (MOR202) is an investigational therapeutic human monoclonal antibody derived from MorphoSys' HuCAL(R) antibody library and directed against CD38.
  • By targeting CD38, felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve the patient's kidney functions.

Global Legumes Market 2019-2023 | Evolving Opportunities with Archer Daniels Midland and B&G Foods | Technavio

Retrieved on: 
Tuesday, January 7, 2020 - 2:15pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200107005682/en/
    Technavio has announced its latest market research report titled global legumes market 2019-2023.
  • In addition, the high consumption of legume-based snacking items is anticipated to positively impact the growth of the global market.
  • The company offers organic aduki beans, organic black beans, organic black-eyed peas, organic black soybeans, organic butter beans, organic white kidney beans, organic garbanzo beans, organic great Northern beans, organic dark red kidney beans, organic navy beans, organic pinto beans, organic small red beans, and Caribbean black beans.
  • The company offers beans dark red kidney, chickpeas, beans black, beans cannellini, beans fava, and beans red kidney under the Progresso brand.